Japanese drugmaker Eisai on Wednesday said its experimental drug lecanemab helped slow thinking declines among people in the early stages of Alzheimer's disease.
Rural Americans with early-onset Alzheimer's disease are less likely than city dwellers to see a specialist and undergo tests that can help them and their families manage, new research reveals.
